People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of ...

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of ...

The Palsonify-treated subjects maintained control, with stable growth hormone levels, symptom scores, and pituitary tumour ...

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general population, ...

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label ...

Crinetics shares PATHFNDR trial data showing oral Palsonify maintained hormone and symptom control in acromegaly patients ...

Most adults with acromegaly reduced IGF-1 levels and improved acromegaly symptoms with once-monthly subcutaneous octreotide ...

Acromegaly is a rare, chronic endocrine disorder characterized by excessive secretion of growth hormone (GH), most commonly resulting from a benign pituitary adenoma.

Retail chatter around Crinetics Pharmaceuticals picked up late Sunday after the company released long-term data for its oral ...

SOUTH SAN FRANCISCO, CA, USA I July 14, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human ...

Although its performance-enhancing effects remain unclear, athletes are thought to be doping themselves with recombinant human growth hormone, which is banned by regulatory authorities for this ...